Earlier this year, Drs. Harrison, Alkhouri, Gawrieh and seven co-authored published a paper in the Journal of Hepatology titled, “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.” This study of 664 non-symptomatic patients revealed a 38% incidence of NAFLDand 14% incidence of NASH. While there were no cases of cirrhosis, 5.9% of patients demonstrated biopsy-diagnosed F2 or F3 NASH. Incidences were higher in several subgroups, notably including patients with Type 2 diabetes or obesity and Hispanic patients.

The three co-authors discuss the motivation to do this study, methods they used and key findings. More gripping were their discussion of implications and the things that surprised them. Louise Campbell and Roger Green asked more questions about the NAFLD and NASH incidence numbers, contrasted them to other US estimates and tied them to other ex-US patient populations.

TOPICS: COVID-19, Diabetes, Diagnostic Tests, EchoSens, Elastography, FibroScan, Fibrosis Level 3, Lean NASH, MRI-PDFF, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, Perspectum Diagnostics, toxic foods, PMPLA3 gene, Hispanic ethnicity, Indigenous people, Pacific Islanders, San Antonio Medical Military Center,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast